• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OptiNose touts Phase III data for exhaled breath drug delivery

September 16, 2016 By Sarah Faulkner

OptiNoseOptiNose touted data from a pair of Phase III clinical trials proving the safety and efficacy of its exhaled breath drug delivery treatment for chronic rhinosinusitis patients with and without polyps.

The company presented the data today at the American Rhinologic Society’s annual meeting in San Diego.

Data from both trials showed limited adverse effects from the fluticasone exhalation delivery system and significant improvement in symptoms and quality of life. Patients with nasal polyps experienced noteworthy reduction in polyp grade, the Pennsylvania-based company reported.

The device is a closed palate, bi-directional exhalation delivery system that’s powered by the user’s breath to propel medication into the nasal cavity. The user exhales into the device, closing their soft palate and sealing off the nasal cavity. The breath carries medication from the device to one side of the nose using a nosepiece.

After passing through the nasal cavity, the exhaled breath balances the pressure across the soft palate and opens a passage so it can exit through the other side of the nose, instead of the patient’s throat or lung.

OptiNose markets the technique as an alternative to oral and injected methods, because its delivery system can manage powder and liquid medication formulas.

“We are thrilled to present Phase III data on the use of our fluticasone exhalation delivery system (EDS-FLU), which we believe can help to better treat this deeply underserved patient population,” CEO Peter Miller said in prepared remarks. “Although almost everyone with this disease tries conventional nasal steroid sprays at some point, including in many instances before or after nasal surgery, many continue to suffer from chronic symptoms. Based on the Phase III data announced today, we are confident that EDS-FLU has potential to really help patients and we look forward to completing the next steps to make this important product available to doctors and patients, including filing of a new drug application with the FDA.”

Filed Under: Clinical Trials, Drug-Device Combinations, Respiratory Tagged With: OptiNose

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS